Trial Profile
A Single Dose Pharmacokinetic Study of LY2409021 Tablet Administered in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2018
Price :
$35
*
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 28 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2014 New trial record